All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Reliable biomarkers are urgently needed for the diagnosis of Parkinson´s and other neurodegenerative diseases. Multiplexing several proteins to evaluate a pattern of analytes may aid in the (differential) diagnosis of several disease conditions \[[@pone.0153564.ref001]--[@pone.0153564.ref004]\]. The proteins α-synuclein (aSyn), β-amyloid~42~ (Aβ~42~), DJ-1 (PARK-7) and total tau (t-tau) are involved in the pathogenesis of neurodegenerative diseases, and have been proposed as biomarkers in cerebrospinal fluid (CSF) for a number of disease conditions with several hallmarks, such as amyloid plaques, neurofibrillary tangles, and Lewy bodies. Hong et al. \[[@pone.0153564.ref005]\] observed lower levels of CSF aSyn and DJ-1 in patients with Parkinson´s disease (PD) and Alzheimer´s disease (AD) than in control subjects. Shi et al. \[[@pone.0153564.ref001]\] and Mollenhauer et al. \[[@pone.0153564.ref006]\] found that aSyn and t-tau protein levels in the CSF are lower in three different aSyn-aggregation-related disorders, including PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) as compared to AD patients or neurological controls (NC). The combination of elevated t-tau protein (and phosphorylated tau protein) with reduced Aβ~42~ levels differentiates AD patients from controls with a sensitivity and a specificity of 80--90% \[[@pone.0153564.ref007]\]. The latter proteins are proposed as CSF biomarkers in research criteria for AD dementia and mild cognitive impairment (MCI) due to AD \[[@pone.0153564.ref008],[@pone.0153564.ref009]\].

Multiplexing plays an important role in patient stratification to identify the presence of a specific disease type or pathology, and in the case of neurological disorders, to exclude other causes of dementia. Previous studies have shown that quantification of Aβ~42~, aSyn, and t-tau may help in the differential diagnosis of neurodegenerative diseases (as for example DLB), as they all reflect processes proximal to a specific neuropathology \[[@pone.0153564.ref010]\]. Although the pathophysiological process of neurodegeneration is related to the formation of oligomers or aggregates of aSyn, Aβ~42~ or tau, resulting in synaptic failures \[[@pone.0153564.ref011],[@pone.0153564.ref012]\], the concentrations of the physiologically occurring monomeric, non-aggregated, form of the proteins are themselves altered during the disease process. Aβ~42~ concentrations are reduced in CSF of patients with AD and dementia with DLB \[[@pone.0153564.ref013]\]. T-tau levels in CSF of DLB patients are lower than in AD and higher than in PD patients \[[@pone.0153564.ref014],[@pone.0153564.ref015]\]. The majority of biomarker studies in aSyn-aggregation-related disorders demonstrate reduced levels of aSyn in the CSF of patients with PD, DLB and MSA \[[@pone.0153564.ref001],[@pone.0153564.ref016],[@pone.0153564.ref017]\].

The aim of this study was to develop a sensitive, first-in-kind, immunoassay-based platform for the simultaneous measurement of aSyn, Aβ~42~, DJ-1 and t-tau in CSF, in order to provide a laboratory-based tool. This, to aid in the objective, reliable and reproducible differential diagnosis of distinct neurodegenerative illnesses, to estimate disease progression, and in the future, to monitor the utility and efficacy of new compounds in therapeutic intervention studies. The major advantage of a multiplex assay format is that it reduces costs and processing time. The entire assay may be performed within less than four hours. In addition, this format may also help increase diagnostic accuracy by measuring four analytes in a single sample wihout the need to run multiple assay plates. Therfore it will also maximize the amount and value of information collected from very small sample volumes \[[@pone.0153564.ref018]\]. A potential disadvantage of multiplex assay formats is any non-specific interaction between antibodies and non-cognate analytes in the reaction mix. Such potential limitations have to be addressed experimentally and, if present, solved operationally. The purpose of our study was to improve conditions and output for investigators when processing human CSF samples for diagnostic purposes (regarding time, convenience, sensitivity, specificity and value of information). Therefore, we built and systematically explored a (first) tetraplex platform for four relevant analytes linked to neurodegenerative disorders.

Methods {#sec002}
=======

All measurements were performed on the MSD Sector Imager 6000. We used Multi-Array Standard Plates for the development of singleplex assays from Meso Scale Discovery^™^ (MSD, Gaithersburg, MD, USA); recombinant proteins which were used as calibrators were from \[[@pone.0153564.ref019]\] (aSyn), Covance (Münster, Germany) (DJ-1), rPeptide (Bogart, GA, USA) (tau protein 441), and MSD (Aβ~42~).

Development of singleplex and multiplex assays {#sec003}
----------------------------------------------

First, we developed single analyte assays on the platform. The singleplex assay procedures and optimization of the assay formats were performed as described previously \[[@pone.0153564.ref020]\]. In a comparable approach, we established sensitive and reproducible singleplex assays for three analytes with the following combination of antibodies: aSyn 3.0 μg/ml rabbit antibody clone 12.1 (kindly provided by Liyu Wu, Epitomics, Burlingame, CA, USA, now available through abcam, Cambridge, UK, as MJFR1) \[[@pone.0153564.ref021]\] as capture antibody and 1.0 μg/ml Syn-1 (BD Biosciences, Heidelberg, Germany) as detection antibody; human DJ-1 antibody AF3995 (R&D Systems, Wiesbaden, Germany) both as capture and as detection antibody at concentrations of 0.15 and 0.1 μg/ml, respectively. T-tau protein was quantified using a combination of 1.0 μg/ml antibody ADx215 for capture and ADx201 (both from ADx Neurosciences, Gent, Belgium) for detection; for the quantification of Aβ~42~, the assay, as developed by MSD \[[@pone.0153564.ref022]\] was incorporated into the tetraplex assay.

Detection antibodies were tagged with \[ruthenium(II) tris-bipyridine-(4-methylsulfonate) NHS ester\] (SULFO-TAG) according to the manufacturer's instructions, except for ADx201, which was biotinylated and used in combination with 0.5 μg/ml streptavidin-SULFO-TAG (MSD). Ruthenium tagged antibodies are quantified using electrochemiluminescence (ECL) technology. Unspecific binding of AF3995 and ADx201 was quenched by adding 0.1% mouse (Rockland Immunochemicals, Limerick, PA, USA) and goat immunoglobulin (Equitech-Bio, Kerrville, TX, USA) to the detection antibody solution.

Calibration curves were prepared with recombinant proteins dissolved in 1% BSA/0.05% PBS-Tween20 (PBS-T) covering a concentration range from 6.1 to 25.000 pg/ml (aSyn, DJ-1, and t-tau protein) or 0.73 to 3000 pg/ml (Aβ~42~). PBS-T was used as blank control. Concentrations as mentioned on the data sheet were used for the study.

The antibodies for the multiplex assay plates were spotted in the facilities of MSD according to their standard operation procedures. The following coating conditions were applied: 0.5x MSD coating concentration of AF3995, 1x coating concentration of MJF1, ADx215 and MSD´s Aβ~42~ capture antibody. Quality control of the coating efficiency was carried out by MSD. For the multiplex assays, we generally blocked and diluted calibrators or samples with Diluent 35 (MSD) instead of 1% BSA/PBS-T. Calibrators and samples were applied to the system at 25 μl for 1h in singleplex and 50 μl for 2h in multiplex assays.

Partial qualification of the multiplex assays {#sec004}
---------------------------------------------

For the qualification experiments, randomly selected CSF samples from controls of the "Kassel cohort" were used. Details on sample processing and diagnostic criteria were published recently \[[@pone.0153564.ref006]\].

Performance tests {#sec005}
-----------------

### Spike-recovery rates {#sec006}

Initial experiments to determine the recovery rates of spiked recombinant proteins in undiluted CSF samples indicated matrix interference for each analyte, resulting in low relative values (29.2%, 20.1%, 46.5, and 86.0% for aSyn, Aβ~42~, DJ-1 and t-tau protein, respectively). Therefore, CSF samples were diluted up to 1:4 in all further experiments. First, recovery rates were determined in CSF, prepared by pooling eight individual CSF samples that were then diluted 1:4 with Diluent 35. In this experiment, calibrator proteins were spiked individually at a final concentration of 250, 500, and 1,000 pg/ml for Aβ~42~ and t-tau protein or 625, 1,250, and 2,500 pg/ml for aSyn and DJ-1. In parallel, all four proteins were also spiked as an entire set at the same concentrations into our pooled CSF specimen. Spiking was performed by adding one volume of individual or combined calibrators to nine volumes of CSF. Endogenous levels of protein were determined by spiking one volume Diluent 35 without calibrators to nine volumes of CSF. The latter is important in order to account for the dilution effect by the addition of the diluent to the CSF. In addition, nine volumes of Diluent 35 were spiked with one volume of the calibrators to verify the exact concentration of each analyte that was spiked into the samples. Finally, we determined spike-recovery rates in individual CSF samples with a procedure identical to that described above, but using only pooled protein calibrators. Addition of proteins was done immediately prior to analysis without additional freezing of samples.

### Dilution linearity and parallelism {#sec007}

Dilution linearity was determined by adding approximately 100-times the endogenous protein concentration of aSyn, DJ-1 and t-tau protein and 25-times the endogenous Aβ~42~ concentration to three individual CSF samples. The final protein concentrations were 20 ng/ml aSyn, 7 ng/ml Aβ~42~, 320 ng/ml DJ-1, and 28 ng/ml t-tau protein. Spiked CSF samples were then serially diluted two-fold in Diluent 35 for analysis.

Parallelism of protein quantification was verified by preparing serial two-fold dilutions of pooled CSF (see above) and three individual CSF samples for analysis. Values were re-calculated taking into account the dilution factor as described \[[@pone.0153564.ref023]\].

Raw data were analyzed using Workbench 3.0 software (MSD).

Our study was carried out in accordance with the Declaration of Helsinki and with the informed written consent of all patients or, in the case of cognitive impairment, their next of kin. Our study was approved by the ethics committees of the University of Göttingen and the Landesärztekammer Hessen (Germany).

### ELISA assays {#sec008}

Quantification of Aβ~42~, t-tau and aSyn were performed according to instructions and protocols provided by the supplier (INNOTEST ELISA Fujirebio Europe, Ghent, Belgium and BioLegend, San Diego, USA).

### Statistical analysis {#sec009}

Results with CVs \<20% for replicate determinations of analyte concentrations were considered reliable according to published guidelines \[[@pone.0153564.ref023]--[@pone.0153564.ref025]\]. Group comparison was performed using the t-test. Statistical analysis was performed using GraphPad Prism Version 5.01 software (San Diego, CA, USA). All other calculations were performed using Microsoft Office Excel 2003.

Results {#sec010}
=======

General assay performance {#sec011}
-------------------------

We first optimized an established, sandwich-type aSyn ELISA \[[@pone.0153564.ref026],[@pone.0153564.ref006]\] and developed new single analyte assays for quantification of DJ-1 and t-tau protein in CSF. All assays were optimized with respect to analytical sensitivity and reproducibility, as described previously \[[@pone.0153564.ref020]\]. Acceptance criteria for qualification of the singleplex assays included a (1) large dynamic range comprising more than 3 orders of magnitude, (2) acceptable dilution linearity for CSF to avoid matrix-effects, and (3) good correlation between signal intensity and protein concentration.

The general characteristics of tetraplex assay performance are summarized in [Table 1](#pone.0153564.t001){ref-type="table"}. Correlation of increase in signal intensity and protein concentration (referred to as Hillslopes) ranged from 1.03 to 1.30 with very low variability.

10.1371/journal.pone.0153564.t001

###### Analytical sensitivity and lower limit of detection for tetraplex assay.

![](pone.0153564.t001){#pone.0153564.t001g}

  -------------- ------ ------ ------
  Hillslope      Mean   SD     %CV
  aSyn           1.2    0.02   1.5
  Aβ~42~         1.3    0.03   2.7
  DJ-1           1.2    0.05   4.6
  Tau            1.0    0.04   3.8
  LLOD (pg/ml)   Mean   SD     %CV
  aSyn           2.0    1.7    87.2
  Aβ~42~         1.2    0.9    71.8
  DJ-1           5.6    4.6    82.3
  Tau            4.1    3.3    81.5
  -------------- ------ ------ ------

Data were calculated from seven individual experiments.

Reproducibility of calibration curves {#sec012}
-------------------------------------

The calibrators were prepared in serial four-fold dilutions ranging from 25,000--0 pg/ml (aSyn, DJ-1 and t-tau protein) or 3,000--0 pg/ml (Aβ~42~). [Fig 1](#pone.0153564.g001){ref-type="fig"} shows the mean results from seven independent experiments (see also [S1 Table](#pone.0153564.s003){ref-type="supplementary-material"}). Data are presented as the percentage of signals at maximum concentration. Variability in signal intensity was low, with CV below 20%, except for the lowest concentration of DJ-1 and some t-tau concentrations. Comparable results were obtained when back-calculated calibrator concentrations were used for analysis.

![Calibration curves of recombinant proteins are highly reproducible.\
Normalized mean values (± standard deviation) from seven independent experiments performed with multiplex assay plates are presented.](pone.0153564.g001){#pone.0153564.g001}

Sensitivity of assay {#sec013}
--------------------

The lower limits of detection (LLOD), as determined by Workbench 3.0 software, varied between 1.24 pg/ml and 5.63 pg/ml and therefore confirmed the high sensitivity of each component of the assay ([Table 1](#pone.0153564.t001){ref-type="table"}). For LLODs, relatively large standard deviations (SD) and coefficients of variance (%CV) were observed, which was to be expected as ELISA usually have considerable variability at the upper and lower ends of their calibration curves, especially within transitions from a linear phase to the plateau phase.

Potential protein-protein interactions {#sec014}
--------------------------------------

Potential interactions in our assay format with other proteins present in the biological fluid specimen were analyzed in two different ways. First, calibration curves of pooled and individual proteins were compared. Calibration curves were compared within the same assay run. As shown in [Fig 2](#pone.0153564.g002){ref-type="fig"} and [S2 Table](#pone.0153564.s004){ref-type="supplementary-material"}, no differences were found between signal intensities or the slopes of calibration curves derived using either individual proteins or pooled calibrators.

![Highly comparable performance in quantification of pooled versus individual recombinant proteins on multiplex assay plates.\
Individual as well as pooled recombinant calibrators were serially diluted by a factor of three for analysis. Signal intensities were comparable under both conditions.](pone.0153564.g002){#pone.0153564.g002}

In a second experiment, the four recombinant calibrators were combined in all possible combinations at 25,000 pg/ml (aSyn, DJ-1 and t-tau protein) and 3,000 pg/ml (Aβ~42~), respectively ([Table 2](#pone.0153564.t002){ref-type="table"} and [S3 Table](#pone.0153564.s005){ref-type="supplementary-material"}). According to the calibration curves, the concentrations of the proteins measured separately nearly always matched the expected concentrations with less than 20% deviation. In these assays, both aSyn and t-tau protein concentrations, regardless of relative amounts, were within 20% of the expected value. In rare cases, Aβ~42~ and DJ-1 quantification generated deviations by \>20% of the expected value. Together these data showed the absence of strong protein-protein interactions under our assay conditions, i.e., when the CSF were dissolved in 1% BSA solution.

10.1371/journal.pone.0153564.t002

###### Analysis of protein interactions.

![](pone.0153564.t002){#pone.0153564.t002g}

       Proteins in assay   Concentration determined (pg/ml)   Percentage of individual protein concentration                                                              
  ---- ------------------- ---------------------------------- ------------------------------------------------ --- ------- ------ ------- ------- ------- ------- ------- -------
  1    x                   x                                  X                                                x   25246   4899   27505   28162   102.5   139.3   119.1   98.5
  2    x                   x                                  x                                                    26429   3583   28378           107.3   101.9   124.4   
  3    x                   x                                                                                   x   25432   3616           28264   103.3   102.8           98.9
  4    x                                                      x                                                x   24464          27952   27343   99.4            121.0   95.7
  5                        x                                  x                                                x           3520   25497   26847           100.1   110.4   93.9
  6    x                   x                                                                                       25720   3480                   104.5   99.0            
  7    x                                                      x                                                    26065          29055           105.9           125.8   
  8    x                                                                                                       x   26470                  31090   107.5                   108.8
  9                        x                                  x                                                            3632   25172                   103.3   109.0   
  10                       x                                                                                   x           3560           27912           101.2           97.7
  11                                                          x                                                x                  21265   26936                   92.1    94.3
  12   x                                                                                                           24625                          100.0                   
  13                       x                                                                                               3517                           100.0           
  14                                                          x                                                                   23097                           100.0   
  15                                                                                                           x                          28581                           100.0

Recombinant proteins were combined in 15 possible combinations (left panel) for quantification. Concentrations for the different proteins determined from pooled sample assays are summarized (middle panel) and normalized for the concentration of the individual protein (right panel). Note the infrequent values with deviations of more than 20% from the expected values.

Dilution linearity {#sec015}
------------------

Dilution linearity was analyzed using serial two-fold dilutions of three individual CSF samples spiked with an approximately 100-fold endogenous concentration of aSyn, DJ-1, and t-tau protein as well as a 25-fold endogenous concentration of Aβ~42~. Results normalized for the third dilution (i.e. a 12.5- or 3.13-fold excess of exogenous protein concentration spiked into CSF) are presented in [Fig 3](#pone.0153564.g003){ref-type="fig"} and [S4 Table](#pone.0153564.s006){ref-type="supplementary-material"}. At protein concentrations exceeding a 12.5-fold endogenous concentration of aSyn, DJ-1 and t-tau protein and a 3.13-fold endogenous Aβ~42~ concentration, normalized protein concentrations differed by more than 20% from the reference concentration. At higher dilutions normalized concentrations were comparable to the reference values until, in the case of t-tau protein, the concentration approached the detection limit and therefore protein quantification became more inconsistent.

![Linearity testing for serial dilution of proteins spiked into CSF samples.\
Three CSF samples were spiked with approximately 100 times the endogenous concentration of aSyn, DJ-1 and t-tau protein as well as 25 times of endogenous Aβ~42~ concentration. CSF samples were serially diluted by a factor of two for analysis. Protein concentrations were normalized for the fourth dilution. Relative protein concentrations are presented. A: aSyn, B: Aβ~42~, C: DJ-1, D: t-tau protein.](pone.0153564.g003){#pone.0153564.g003}

Parallelism {#sec016}
-----------

Parallelism was analyzed using serial two-fold dilutions of CSF, and using undiluted CSF as the highest concentration. Results normalized for concentrations in CSF diluted at 1:8 are presented in [Fig 4](#pone.0153564.g004){ref-type="fig"} and [S5 Table](#pone.0153564.s007){ref-type="supplementary-material"}. Results of normalized protein concentrations became more comparable with increasing dilution. While protein concentrations, as measured in undiluted CSF and 1:2 diluted CSF specimens, were significantly lower than the reference concentration, most of the values determined at 1:4 were comparable to the reference data. For aSyn and Aβ~42~, one out of four samples measured at 1:4 dilution deviated by slightly more than 20% from the reference value measured at 1:8 dilution (20.5 and 22%, respectively). These results point to matrix effects interfering with the protein quantification at higher CSF concentration.

![Parallelism of analyte quantification in serially diluted CSF samples.\
Pooled CSF and three individual CSF samples were serially diluted by a factor of two for analysis. Protein concentrations were normalized for the 1:8 dilutions. A: aSyn, B: Aβ~42~, C: DJ-1, D: t-tau protein.](pone.0153564.g004){#pone.0153564.g004}

Accuracy rates (recovery of spiked proteins) {#sec017}
--------------------------------------------

Initial experiments using undiluted CSF samples to analyze recovery rates for spiked proteins indicated that matrix effects significantly inhibited protein quantification. We therefore used a pool of eight distinct CSF samples diluted at 1:4 with Diluent 35 and spiked with individual or pooled calibrators. Recovery rates improved considerably following CSF dilution: Using three different spike concentrations of each protein, mean recovery rates for individually spiked proteins were determined as 70.5 ± 2.6% for aSyn, 73.0 ± 4.3% for Aβ~42~, 105.7 ± 3.0% for DJ-1, and 119.5 ± 9.7% for t-tau protein ([Table 3A](#pone.0153564.t003){ref-type="table"}). Similarly, slightly lower recovery rates were found when pooled proteins were spiked into pooled CSF, where recovery rates were 60.7 ± 9.7% for aSyn, 58.2 ± 13.3% for Aβ~42~, 98.6 ± 1.8% for DJ-1, and 106.6 ± 9.0% for t-tau protein ([Table 3A](#pone.0153564.t003){ref-type="table"}). This experiment was repeated with four individual CSF samples using pooled proteins. Under these conditions recovery rates were at 64.3 ± 3.6%, 55.5 ± 3.7%, 98.0 ± 5.4, and 95.7 ± 7.1% for aSyn, Aβ~42~, DJ-1 and t-tau protein, respectively ([Table 3B](#pone.0153564.t003){ref-type="table"}, see also [S6 Table](#pone.0153564.s008){ref-type="supplementary-material"}).

10.1371/journal.pone.0153564.t003

![](pone.0153564.t003){#pone.0153564.t003g}

  ---------------------------------------------------------------------------- --------------------- ------------------------ -------------------- ------------------------ -------------------- ------------------------ -------------------- ------------------------
  A. %Recovery rates of spiked protein calibrators into pooled CSF                                                                                                                                                                             
                                                                               aSyn                  Aβ~42~                   DJ-1                 tau protein                                                                                 
  spike concentration                                                          pooled calibrators    individual calibrators   pooled calibrators   individual calibrators   pooled calibrators   individual calibrators   pooled calibrators   individual calibrators
  High                                                                         61.1                  69.6                     55.2                 69.8                     97.3                 102.8                    99.5                 115.1
  Medium                                                                       50.8                  73.2                     46.7                 72.2                     97.8                 108.7                    103.5                130.6
  Low                                                                          70.2                  68.5                     72.8                 77.8                     100.7                105.4                    116.7                112.9
  Mean                                                                         60.7                  70.5                     58.2                 73.0                     98.6                 105.7                    116.7                112.9
  SD                                                                           9.7                   2.6                      13.3                 4.3                      1.8                  3.0                      9.0                  9.7
  B. % Recovery rates of spiked calibrators into four individual CSF samples                                                                                                                                                                   
                                                                               aSyn                  Aβ~42~                   DJ-1                 tau protein                                                                                 
  spike concentration                                                          mean recovery (±SD)                                                                                                                                             
  high                                                                         63.1 (19.8)           55.6 (15.6)              91.9 (5.19           103.5 (14.6)                                                                                
  medium                                                                       68.3 (21.8)           59.1.(15.0)              102.2 (2.6)          94.0 (11.5)                                                                                 
  low                                                                          61.4 (16.9)           51,7 (13.4)              99,8 (3.3)           89,6 (7.2)                                                                                  
  mean                                                                         64.3                  55.5                     98.0                 95.7                                                                                        
  SD                                                                           3.6                   3.7                      5.4                  7.1                                                                                         
  ---------------------------------------------------------------------------- --------------------- ------------------------ -------------------- ------------------------ -------------------- ------------------------ -------------------- ------------------------

Except for DJ-1, relatively high standard deviations of recovery rates were noted with individual CSF samples ([Fig 5](#pone.0153564.g005){ref-type="fig"}). We observed that in two out of four CSF samples (CSF2 and CSF4) recovery rates were lower than for CSF1 and CSF3. This implies that although CSF samples were diluted by a factor of four to reduce matrix effects, these were still observable, albeit much less so compared to undiluted CSF samples. One might consider in the future a higher dilution factor for such samples, as long as the working range for analyzing the samples is not negativelyaffected.

![Recovery rates of spiked calibrators into individual CSF samples.\
Recombinant calibrators were spiked at three different concentrations into four CSF samples. Concentrations of spike solutions and endogenous protein concentrations were determined in parallel. Recovery rates were calculated taking into account both the endogenous CSF concentration and the protein concentration of the spike solutions. A: aSyn, B: Aβ~42~, C: DJ-1, D: t-tau protein.](pone.0153564.g005){#pone.0153564.g005}

### Intra- and inter-assay variability {#sec018}

Intra-assay reproducibility was determined by measuring CSF samples in duplicate. In total, 36 undiluted CSF samples were measured and 192 were measured at 1:4 dilution. Most samples showed CVs below 20%. For undiluted CSF samples, CV values above 20% were found in 3 cases for aSyn (range: 23.9--35.4%), 5 cases for Aβ~42~ (range: 22.9--52.9%), 2 cases for DJ-1 (range: 23.3--30.5%) and 3 cases for t-tau protein (range: 21.9--30.0%). For diluted CSF samples, CVs above 20% were found in ten cases for aSyn (range: 20.4--28.3%), 16 cases for Aβ~42~ (range: 22.5--46.3%), one case for DJ-1 (CV: 28.7%) and 27 cases for t-tau protein (range: 20.5--141.1%).

Inter-assay variability was determined by measuring 40 CSF samples at 1:4 dilution in two independent experiments. Two CSF samples showed CVs above 20% for quantification of Aβ~42~ (23.2 and 27.5%). T-tau protein quantification yielded CVs above 20% in 20 cases. With the exception of four CSF samples that exhibited relatively high t-tau protein concentrations, the other 16 CSF samples had t-tau protein concentrations at or near the lower limit of detection (i.e. below 20 pg/ml). Quantification of aSyn and DJ-1 concentrations always gave CVs below 20%.

To compare performances between our tetraplex prototype and individual commercial platforms in a larger sample set, we chose a subset of 83 CSF specimens with enough remaining volume for quantification in multiple different assays for values of Aβ~42~, t-tau and aSyn. As expected, the results revealed a high correlation between them for all three proteins tested (R^2^ for aSyn: 0.767, for Aβ~42~: 0.559, for Tau: 0.725) ([S1 Fig](#pone.0153564.s001){ref-type="supplementary-material"}).

Comparison of quantification results in singleplex and multiplex assays {#sec019}
-----------------------------------------------------------------------

For a first pilot set of CSF samples submitted for diagnostic purposes in the differential diagnosis of motoric impairment, we analyzed eight patients with normal pressure hydrocephalus (NC) without evidence of typical PD and eight patients with idiopathic PD. Twenty five μl of CSF were measured undiluted both in our singleplex assays for aSyn, DJ-1 and t-tau protein and by tetraplex assay ([Fig 6](#pone.0153564.g006){ref-type="fig"} and [S7 Table](#pone.0153564.s009){ref-type="supplementary-material"}). Overall concentrations of aSyn were lower in the tetraplex assay than by singleplex assay. The reverse was true for DJ-1. The t-tau protein results were not statistically different between singleplex and tetraplex assays. Samples from PD patients showed lower protein levels of aSyn, DJ-1 and t-tau protein as compared to NC patients on the multi- and singleplex assay. This difference was statistically different for DJ-1 and t-tau protein in singleplex quantifications and also for t-tau protein in multiplex quantifications ([Table 4](#pone.0153564.t004){ref-type="table"}). Protein concentrations determined in both assay formats were highly correlated (R^2^ for aSyn: 0.504, for DJ-1: 0.791, for Tau: 0.726) ([S2 Fig](#pone.0153564.s002){ref-type="supplementary-material"}).

![Quantification of CSF samples in singleplex versus multiplex assays.\
Eight CSF samples from neurological controls and patients with PD were analyzed both in singleplex (except for Aβ~42~) and (SP) multiplex assays (MP). Results were obtained from non-diluted samples.](pone.0153564.g006){#pone.0153564.g006}

10.1371/journal.pone.0153564.t004

###### P-value summary for comparison of singleplex and multiplex quantification.

![](pone.0153564.t004){#pone.0153564.t004g}

  p-value                           aSyn     Aβ~42~   DJ-1       tau protein
  --------------------------------- -------- -------- ---------- -------------
  singleplex NC vs. singleplex PD   0.2606   n.d.     0.0458     0.0023
  Multiplex NC vs. multiplex PD     0.4172   0.8753   0.1548     0.0112
  singleplex NC vs. multiplex NC    0.001    n.d.     \<0.0001   0.8899
  singleplex PD vs. multiplex PD    0.0007   n.d.     \<0.0001   0.1281

Discussion {#sec020}
==========

In this study we describe the first generation of a tetraplex immunoassay that simultaneously quantifies aSyn, DJ-1, Aβ~42~ and t-tau protein in CSF on an ECL-platform; furthermore, its performance was substantiated according to the most stringent criteria, such as those published in internationally recommended guidelines for new assay validation \[[@pone.0153564.ref023]--[@pone.0153564.ref025]\]. With the recent increasing number of multiplex assays developed for multiple disciplines in clinical management and preclinical studies, researchers and clinicians have the opportunity to measure multiple biomolecules in parallel. Application of ECL-detection moreover allows a sensitive quantification of up to ten analytes in parallel.

Singleplex immunoassays are suitable to measure individual protein concentrations without the problem of potential interference of antibodies. However, multiple assays need to be performed to quantify several proteins. Furthermore traditional ELISAs often require sample incubation over night.

The major advantage of a multiplex assay format is that it reduces time, cost and processing time. The whole assay may be performed within less than four hours. In addition this format may help to increases diagnostic accuracy by measuring four analytes in a single sample without the need to run multiple assay plates, which can introduce variability due to multiple handling steps of the same stock specimen. Therefore it is desirable to derive considerably more information from minimal sample volumes \[[@pone.0153564.ref018]\]. A disadvantage of multiplex assay formats is the occurrence of non-specific interaction of the antibodies and analytes used in the reaction. These have to be addressed experimentally, which we did in the case of our chosen four analytes.

The ECL technology is widely used in different research areas \[[@pone.0153564.ref027],[@pone.0153564.ref028]\]. Most studies used commercially available assays, which were usually not extensively validated. Detailed studies on validation of custom-made ECL assays have been published recently \[[@pone.0153564.ref029],[@pone.0153564.ref030]\].

Our assay development efforts were aimed at multiplexing four proteins associated with Parkinson´s or Alzheimer´s disease pathology, i.e. aSyn, DJ-1, t-tau protein and Aβ~42~, in order to improve diagnostic accuracy by identifying PD pathology or by excluding AD pathology.

The general performance of our established multiplex assay as indicated by the Hillslopes and LLODs showed high sensitivity for each of the four proteins of interest. Hillslopes define the correlation of increases in concentration and signal intensity. A sensitive assay should have very close correlation between these two metrics. An ideal Hillslope of 1 demonstrates that a two-fold or ten-fold increase in concentration corresponds to a two-fold or ten-fold increase in signal intensity, respectively. In our experiments we observed mean Hillslopes of 1.30 for Aβ~42~. These data show that in the case of Aβ~42~ a ten-fold increase in protein concentration corresponds to a 13-fold increase in signal intensity. In other words, a 13-fold increase in signal intensity is required to measure a ten-fold increase in protein concentration. For the other proteins the correlation was much better. Mean Hillslopes ranged from 1.03 to 1.15. In addition, LLODs for all proteins were far lower than the lowest concentrations measured in our clinical samples (1.24--5.63 pg/ml).

Reproducibility of calibration curves {#sec021}
-------------------------------------

The calibration curves were found to be highly reproducible. The mean signal intensities obtained at all concentrations performed in duplicate in seven experiments gave CV values of less than 20% in most cases, indicating that quantification over the entire concentration range is reliable \[[@pone.0153564.ref023]--[@pone.0153564.ref025]\].

Intra- and inter-assay variability {#sec022}
----------------------------------

Both in undiluted and in diluted CSF we found that most of the duplicate determinations had CVs below 20%, except for t-tau protein. Signal readings for t-tau protein in most cases was detected at the lower end of the calibration curve, where slight changes in signal reading have a strong impact on concentration assignment. This is very evident when diluted samples were analyzed. In this case the proportion of t-tau protein measurements with high CVs increased and therefore became less reliable. Quantification of the other proteins was comparable in two experiments. These results clearly demonstrate that finding a single dilution factor that permits the measurement of multiple proteins in a given sample may be difficult, as has been reported \[[@pone.0153564.ref003]\].

Potential interaction of proteins {#sec023}
---------------------------------

All proteins of interest in this study tend to form either homo- or hetero-oligomers or to promote aggregation of other proteins \[[@pone.0153564.ref031]--[@pone.0153564.ref033]\]. We therefore analyzed whether significant protein interactions occurred by comparing 1) the performance of calibration curves of individual proteins with those of pooled calibrators and 2) co-incubation of all proteins of interest at very high concentrations in all possible combinations. Neither the comparison of curves for individual or pooled calibrators nor mixtures of proteins at high concentration give any hint of protein aggregation.

Accuracy (recovery) {#sec024}
-------------------

Recovery rates determined in several experiments showed that these were higher than 50% for all proteins and nearly 100% for t-tau protein and DJ-1. They were slightly lower for aSyn and Aβ~42~. These results clearly show that the combinations of antibodies used in this study are suitable for quantification of the proteins in a multiplex format. We observed that using individual CSF samples led to variable recovery rates. This may be attributed to matrix effects which can be reduced by further diluting the CSF. Further reduction of CSF concentration will also reduce t-tau protein concentrations to levels below the limit of detection, at least in our cohort. The analytical sensitivity of the t-tau assay can be improved by combining it with other monoclonal antibodies or modifying the method of labelling the detector antibody. Nevertheless, this multiplex assay format may be suitable for analysing t-tau protein concentrations in other neurodegenerative diseases that are accompanied by significant cell destruction (for example Alzheimer's disease and Creutzfeldt-Jakob disease).

Our multiplex assay does not necessarily preclude problems that arise with immunoassay performance in general, such as lab-to-lab variability, lot-to-lot variability, lack of certified reference material, etc. \[[@pone.0153564.ref034],[@pone.0153564.ref035]\]. However, increasing implementation of automated systems promises to limit errors generally associated with the performance of ELISAs and comparable assays.

Comparison of test results between singleplex and multiplex assays {#sec025}
------------------------------------------------------------------

We compared the quantification results of our multiplex assay with those of singleplex assays in a small cross-sectional study. In these experiments we found that the general trend was comparable between both assay formats, in that the CSF samples from the PD patients had lower concentrations of aSyn, DJ-1 and t-tau protein than those from the patients with normal-pressure hydrocephalus used as clinical controls. These results are consistent with other studies investigating CSF levels of these proteins in PD patients and healthy controls \[[@pone.0153564.ref001],[@pone.0153564.ref005],[@pone.0153564.ref036]\]. Interestingly, aSyn revealed lower concentrations in the multiplex assay than in singleplex assays, while the reverse was true for DJ-1. T-tau protein levels were determined to be comparable in both assays. The reason for these discrepancies is currently not known and will be investigated in further experiments. The most obvious explanation is that antibody concentrations differed between the two assays. Compared to custom-made singleplex assays, much higher antibody concentrations are used to coat spots on multiassay plates. This fact in combination with spatial reading of the comparably small spots on multiassay plates might be responsible for this observation. In addition, we found that Hillslopes differed between assay formats, further contributing to differences in concentration calculations. Results from the analysis of parallelism clearly demonstrated that with increasing CSF dilution the relative analyte concentration increased. Matrix effects seem to interfere with quantification of our proteins of interest, in particular for aSyn and Aβ~42~. We speculated that similar observations will be made when diluted samples from PD patients are compared to neurological controls. Currently we are not able to definitely state whether the effect of diluting CSF will lead to a more comparable concentration assignment between the two different assay formats. The answer would require that in the case of DJ1 sample dilution must have a very strong effect in the singleplex assay in order get comparable results to the multiplex assay while for α-Synuclein the effect should be higher in the multiplex assay. Further experiments are needed to address this issue.

We found that for defined calibrator concentrations much higher ECL signals were measured on multiplex than on singleplex plates. This was also seen in the samples, although not to the same extent. ECL signals for t-tau protein calibrators and samples were comparably increased on multiplex plates (\~3.5-fold). With aSyn, the ECL signals for calibrators and samples on multiplex plates increased by factors of four and two, respectively, while the calibrator readings for DJ-1 increased \~20-fold and sample readings \>70-fold on multiplex plates. Therefore DJ-1 concentrations were assigned much higher levels on multiplex plates and aSyn concentrations to lower levels as compared to singleplex plates.

Conclusions {#sec026}
===========

We demonstrate the generation and careful characterization of a tetraplex assay for the simultaneous quantification of PD- and AD-associated proteins in as little as 50 μl of CSF volume. The assay is easy to perform, requires less hands-on time as compared to conventional ELISAs and saves precious clinical material. Further experiments are required to validate and apply the assay further, such as to demonstrate its usefulness in routine laboratory practice processing larger numbers of samples than shown here. Major advantages of the tetraplex assay are (1) its superior sensitivity, (2) the broad dynamic range, (3) its high degree of reproducibility; and importantly, (4) the one-step readout of multiple analytes in the same specimen. We are aware that our assay also needs validation by independent groups (e.g. round robin trials \[[@pone.0153564.ref035]\]). Due to the complexity of multiplexing there is a theoretical risk of non-specific interactions between antibodies and analytes (largely ruled out here). A potential limitation we see is that smaller batch productions multiplex assay plates less practical, and hence would raise the cost versus the production of larger ones. Nevertheless, with increasing need for an objective multiplex format assays---such as ours---will become overall cheaper than running separate experiments of multiple analytes.

In summary, our tetraplex platform now permits a more objective, faster and more informative interrogation of small volumes of CSF from patients with incurable disorders of the brain. We envision that technological advances such as this one will serve patient stratification, improve the design of clinical trials, allow for disease monitoring, and thus, increase the chance for an urgently needed, positive outcome in future intervention studies.

Supporting Information {#sec027}
======================

###### α-Synuclein (A), Aβ42 (B) and Tau protein (C) concentrations measured in either commercially available or validated ELISA assays or multiplex assay are highly correlated.

(DOC)

###### 

Click here for additional data file.

###### α-Synuclein (A), DJ-1 (B) and Tau protein (C) concentrations measured in singleplex and multiplex assays are highly correlated.

(DOC)

###### 

Click here for additional data file.

###### Raw data for standard curves performed in seven independent experiments.

Indicated are mean signal readings and standard deviations. The relatively high standard deviation of Tau protein standard curves may be explained by usage of two different kit lots. This table refers to [Fig 1](#pone.0153564.g001){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data for standard curves on individual and pooled standards.

Raw data for standard curves performed on individual standards and pooled standards (in duplicate) in a single experiment are indicated. Signal readings for both standard curve formats are highly comparable. This table refers to [Fig 2](#pone.0153564.g002){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data of signal readings (S3A Table) and concentrations (in pg/ml; S3B Table) of specific and unspecific interactions in multiplex assays.

Indicated are row positions of a 96 well plate, spot with identity of capture antibodies and the respective results. Positions where specific results were expected are highlighted in grey. In most assay wells no unspecific interactions were observed. Only in a few cases unspecific interactions were found (indicated in red in S3B Table). This table refers to [Table 2](#pone.0153564.t002){ref-type="table"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data of protein concentrations in dilution linearity experiments.

Indicated are protein concentrations from CSF samples spiked with very high protein concentrations (left section). Results were then adjusted for the fourth dilution (middle section) and normalized for this dilution step (right section). This table refers to [Fig 3](#pone.0153564.g003){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data of protein concentrations in parallelism experiments.

Indicated are protein concentrations from serially diluted CSF samples (left section). Results were then adjusted for dilution factors (middle section) and normalized for the fourth dilution step (right section). This table refers to [Fig 4](#pone.0153564.g004){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data of protein concentrations from spike recovery experiments.

Indicated are protein concentrations in spike solutions used in the experiment as well as protein concentrations measured in CSF samples spiked at different concentrations (left section). Endogenous protein concentrations were subtracted and recovery rates were calculated based on proteins concentrations in spike solutions and spiked CSF samples. This table refers to [Fig 5](#pone.0153564.g005){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.

###### Raw data of protein concentrations measured in CSF samples from eight neurological control patients and eight patients with Parkinson´s disease in singleplex and multiplex assays.

This table refers to [Fig 6](#pone.0153564.g006){ref-type="fig"}.

(DOC)

###### 

Click here for additional data file.
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